- Home
- NVO vs LLY Comparison
NVO vs LLY Comparison
Compare NVO & LLY Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVO | LLY |
|---|---|---|
| Founded | 1923 | 1876 |
| Country | Denmark | United States |
| Employees | 69500 | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 208.2B | 979.6B |
| IPO Year | N/A | 2007 |
Fundamental Metrics
Financial Performance| Metric | NVO | LLY |
|---|---|---|
| Price | $45.83 | $1,191.86 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 19 |
| Target Price | $51.00 | ★ $1,218.84 |
| AVG Volume (30 Days) | ★ 10.6M | 2.0M |
| Earning Date | 05-06-2026 | 04-30-2026 |
| Dividend Yield | ★ 3.19% | 0.81% |
| EPS Growth | N/A | ★ 95.99 |
| EPS | N/A | ★ 16.19 |
| Revenue | N/A | ★ $65,179,000,000.00 |
| Revenue This Year | N/A | $27.15 |
| Revenue Next Year | $3.70 | $16.04 |
| P/E Ratio | ★ $13.60 | $73.68 |
| Revenue Growth | N/A | ★ 44.70 |
| 52 Week Low | $35.12 | $625.90 |
| 52 Week High | $64.16 | $1,249.45 |
Technical Indicators
Market Signals| Indicator | NVO | LLY |
|---|---|---|
| Relative Strength Index (RSI) | 40.53 | 57.00 |
| Support Level | $42.72 | $1,032.70 |
| Resistance Level | $46.92 | $1,240.73 |
| Average True Range (ATR) | 1.34 | 34.58 |
| MACD | -0.75 | -3.78 |
| Stochastic Oscillator | 21.22 | 78.01 |
Price Performance
Historical ComparisonAbout NVO Novo Nordisk A/S
With roughly one-third of the global branded diabetes treatment market, Novo Nordisk is the leading provider of diabetes care products in the world. Based in Denmark, the company manufactures and markets a variety of human and modern insulins, injectable diabetes treatments such as GLP-1 therapy, oral antidiabetic agents, and obesity treatments. Novo also has a biopharmaceutical segment (contributing less than 10% of revenue) that specializes in protein therapies for hemophilia and other disorders.
About LLY Eli Lilly and Company
Eli Lilly is a drug firm with a focus on neuroscience, cardiometabolic, cancer, and immunology. Lilly's key products include Verzenio and Jaypirca for cancer; Mounjaro, Zepbound, Foundayo, Jardiance, Trulicity, Humalog, and Humulin for cardiometabolic; and Taltz and Olumiant for immunology.